On November 5, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two upcoming scientific conferences, including the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Theranostics Conference, taking place November 4–7 in Bethesda, MD, USA and the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC), taking place December 4–6 in Scottsdale, AZ, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentations
2026 SNMMI Theranostics Conference
Title: How much Target Expression is Enough? Learnings from advancing MP0712, a DLL3 Radio-DARPin for SCLC, into the clinic
Format: Oral presentation
Presenter: Daniel Steiner, Ph.D., SVP Targeted Radio Therapeutics
Session: Future of Theranostics – Part 1
Date and time: Saturday, November 7, 8:40 – 9:00 am EST
Location: Bethesda North Marriott Hotel & Conference Center, Bethesda, Maryland
NACLC 2026
Title: [212Pb]Pb-MP0712 in patients with small cell lung cancer (SCLC) and other Delta-like ligand 3 (DLL3) expressing solid tumors: Initial dose escalation data from a first-in-human Phase 1/2a study
Format: Poster presentation
Presenting author: Ticiana Leal, M.D., Winship Cancer Institute of Emory University, Atlanta, GA
Date and time: Saturday, December 5, 2026, 4:15 – 5:45 pm MST
Location: Grand Hyatt Scottsdale Resort, Scottsdale, Arizona
The presentations will be made available on Molecular Partners’ website after the presentations.
(Press release, Molecular Partners, NOV 5, 2026, View Source [SID1234674196])